Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication.
7 reports, 1 independent
Updated Jul 28
Gone quiet
- Reports
- 7
- Developments
- 2
- Repetition
- 86%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- FDA granted Priority Review for Syndax's sNDA on June 25, 2025.Sub-event
Syndax uses LinkedIn for company communication regarding its FDA-approved pipeline.1 source
Keep exploring
The entities involved
- FDA
-
Syndax Pharmaceuticals
business
Nothing else this week.
-
LinkedIn
American social networking website for people in professional occupations
Related events
- Edgewise Therapeutics announced news from Boulder, Colorado, and utilizes LinkedIn for its public communication.
- Nasdaq directs interested parties to LinkedIn for company information.
- Legend Biotech and Johnson & Johnson announced their collaboration on CARVYKTI, while Legend Biotech also utilized LinkedIn for professional presence.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- LinkedIn and Hashdex co-developed the Nasdaq CME Crypto Index, while LinkedIn continues to be used for professional outreach.
Coverage
Newest first; wire copies grouped- GlobeNewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmac
- GlobeNewswireSyndax Announces Participation in September Investor Conferences NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advanc
- GlobeNewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmace
- GlobeNewswireSyndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a co
- Unknown outlet